The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer

Cancer Research

Volumn 65, Issue 1, 2005, Pages 18-25

  Chu, Isabel ^a,c   Blackwell, Kimberly ^d,e   Chen, Susie ^a   Slingerland, Joyce ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d DUKE CANCER INSTITUTE   (United States)

^e Box 3893DUMC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P27; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT;

BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TAMOXIFEN;

EID: 11244257032     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
2. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
5. Borg A, Tandon AK, Sigurdsson H, et al. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-7.
6. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002;71:67-75.
7. Nicholson S, Wright C, Sainsbury JR, et al. Epidermal growth factor receptor (EGFR) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Mol Biol 1990;37:811-4.
8. Lenferink AEG, Simpson Jf, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu plus MMTV/TGF-α bigenic mice. Proc Natl Acad Sci U S A 2000;97:9609-14.
9. Coleman KM, Smith CL. Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci 2001;6:D1379-91.
10. Musgrove EA, Sutherland RL. Cell cycle control by steroid hormones. Cancer Biol 1994;5:381-9.
11. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 2000;97:9042-6.
12. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-4.
13. Le Goff PL, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor. J Biol Chem 1994;269:4458-66.
14. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids 2000;65:227-51.
15. Jordan VC. Studies on the estrogen receptor in breast cancer: 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 1995;36:267-85.
16. De Placido S, Carlomagno C, De Laurentiis M, Bianco AR. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res Treat 1998;52:55-64.
17. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85-95.
18. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995;10:2435-46.
19. Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032-44.
20. 1-phase progression. Genes Dev 1999;13:1501-12.
21. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10-7.
22. Kip1. Breast Cancer Res Treat 1998;52:29-41.
23. Donovan JC, Milic A, Slingerland JM. Constitutive MEK/MAPK activation leads to p27Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 2001;276:40888-95.
24. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003;284:122-30.
25. Lees E, Faha B, Dulic V, Reed SI, Harlow E. Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev 1992;6:1874-85.
26. Xia WL, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63.
27. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
28. Castoria G, Migliaccio A, Bilancio A, et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 2001;20:6050-9.
29. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003;9:511-5S.
30. Rabenoelina F, Semlali A, Duchesne M-J, Freiss G, Pons M, Badia E, Effect of prolonged hydroxytamoxifen treatment of MCF-7 cells on mitogen activated kinase cascade. Int J Cancer 2002;98:698-706.
31. 1 arrest. Nat Med 2002;8:1153-60.
32. Connor CE, Norris JD, Broadwater G, et al. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res 2001;61:2917-22.
33. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer [abstract 3006]. Proc Am Soc Clin Oncol 2004;23:196.
34. Carroll JS, Prall OW, Musgrove EA, Sutherland RL. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem 2000;275:38221-9.
35. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
36. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
37. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
38. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation receptor overexpression does not determine growth dependency. Mol Cel Biol 2000;20:3210-23.
39. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-44.
40. Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci U S A 1999;96:11217-22.
41. Kenny FS, Hui R, Musgrove EA, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999;5:2069-76.
42. Alle KM, Henshall SM, Field AS, Sutherland RL. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998;4:847-54.
43. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21.
44. Wilckine NR, Prall OW, Musgrove EA, Sutherland RL. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 1997;3:849-54.
45. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997;11:957-72.
46. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
47. Dees EC, Burris H, Hurwitz H, et al. Clinical summary of 67 heavily pre-treated patients with metastatic breast carcinomas treated with GW572016 in phase Ib study [abstract 3188]. Proc Am Soc Clin Oncol 2004;241.
48. Migliaccio A, Piccolo D, Castoria G, et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998;17:2008-18.
49. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538-41.
50. Song RX, Barnes CJ, Zhang ZG, Bao YD, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor a to the plasma membrane. Proc Natl Acad Sci U S A 2004;101:2076-81.
51. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83.
52. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
53. Denton RR, Koszewski NJ, Notides AC. Estrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding. J Biol Chem 1992;267:7263-8.
54. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 1993;7:992-8.
55. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
56. Kurokawa H, Lenferink AE, Simpson Jf, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
57. Bundred NJ, Chan K, Anderson NG. Studies of epidermal growth factor receptor inhibition in breast cancer. Endocr Relat Cancer 2001;8:183-9.
58. Belsches-Jablonski AD, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001;20:1465-75.
59. deFazio A, Chiew YE, Sini RL, Janes PW, Sutherland RL. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 2000;87(4):487-98.